CAS: 1456696-14-2; (S,E)-4-(Dimethylamino)-N-(4-Hydroxy-7-((Tetrahydrofuran-3-yl)Oxy)Quinazolin-6-yl)But-2-Enamide
- 英文名称(S,E)-4-(Dimethylamino)-N-(4-Hydroxy-7-((Tetrahydrofuran-3-yl)Oxy)Quinazolin-6-yl)But-2-Enamide
- 中文名称阿法替尼杂质J
- IUPAC名称(S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide
- 其它别名Afatinib Impurity J; Afatinib Impurity J Hcl; (2E)-N-[3,4-Dihydro-4-Oxo-7-[[(3S)-Tetrahydro-3-Furanyl]Oxy]-6-Quinazolinyl]-4-(Dimethylamino)-2-Butenamide; Afatinib Impurity 8/(2E)-N-[3,4-Dihydro-4-Oxo-7-[[(3S)-Tetrahydro-3-Furanyl]Oxy]-6-Quinazolinyl]-4-(Dimethylamino)-2-Butenamide; (2E)-4-(Dimethylamino)-N-{4-Oxo-7-[(3S)-Tetrahydro-3-Furanyloxy]-1,4-Dihydro-6-Quinazolinyl}-2-Butenamide; 2-Butenamide, N-[3,4-Dihydro-4-Oxo-7-[[(3S)-Tetrahydro-3-Furanyl]Oxy]-6-Quinazolinyl]-4-(Dimethylamino)-, (2E)-; (S,E)-4-(Dimethylamino)-N-(4-Oxo-7-((Tetrahydrofuran-3-Yl)Oxy)-3,4-Dihydroquinazolin-6-Yl)But-2-Enamide; Afatinib B
- CAS编号1456696-14-2
- FDA UNII编号:8P652B3QLZ
- 分子式:C18H22N4O4分子量:358.4
- 产品CID: 691286
- 产品分类分析化学 → 标准品 → 药典标准品和杂质标准品
MSDS等安全信息
上下游产品
7-chloro-6-nitro-4(3H)-quinazolinone合成工艺路线路线简述
📜(S)-6 Nitro-7-((Tetrahydrofuran-3-yl)Oxy)Quinazolin-4(3H)-One置于草酰氯,铁粉,溶剂黄146,N,N-二甲基甲酰胺体系中,用 四氢呋喃,乙醇,水 用作溶剂,化学反应 1.83H,反应生成阿法替尼杂质j
参考文献: Radiolabeled Quinazoline Derivatives[fr] Dérivés De Quinazoline Radiomarqués
标题: Radiolabeled Quinazoline Derivatives[fr] Dérivés De Quinazoline Radiomarqués
摘要:本发明描述了一种新型正电子发射断层扫描(pet)或单光子发射计算机断层扫描(spect)成像的放射性示踪剂.具体而言,本发明涉及18F标记的阿法替尼,作为pet或spect示踪剂用于成像表皮生长因子受体(egfr,Erbb1)和人类表皮生长因子受体2(her2,Erbb2),以及用于其合成的前体化合物,制备18F标记阿法替尼的方法,以及在体内诊断,肿瘤成像或基于egfr(erbb1)和her2(erbb2)突变状态的患者分层的用途.
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2905310000-1,2-乙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2015368230-A1
优先权日:2013-02-01
标 题:Radiolabeled quinazoline derivatives
发明人：SLOBBE PAUL; POOT ALEX JOHANNES; VAN DONGEN AUGUSTINUS ANTONIUS MARIA SILVESTER; NIESSEN HEIKO; WINDHORST ALBERT DIRK
权利人:BOEHRINGER INGELHEIM INT; STICHTING VU VUMC
摘要:Novel radiotracer for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging are described. Specifically, the invention relates to 18 F-labeled afatinib suitable as a PET or SPECT tracer for imaging epidermal growth factor receptor (EGFR, erbB1) and human epidermal growth factor receptor 2 (Her2, erbB2), to a precursor compound for use in its synthesis, to methods for the preparation 18 F-labeled afatinib, as well as to the use thereof in in vivo diagnosis, tumor imaging or patient stratification on the basis of mutational status of EGFR (erbB1) and Her2 (erbB2).
